Press "Enter" to skip to content

China’s leading drugmaker confirmed accounting fraud

One of China’s leading drugmakers has asked the Shanghai stock exchange to suspend trading of its shares from Monday after securities regulators confirmed the company faked its financial statements between 2016 and 2018.

The Shanghai-listed Kangmei Pharmaceutical Co. Ltd was found to have used fake bank deposit slips to inflate its cash holding, forged documents for non-existent business activities and transferred its funds to affiliates to trade its own stocks, said the China Securities Regulatory Commission (CSRC) in a statement on Friday.

Kangmei on Saturday confirmed that it moved 8.88 billion yuan through its affiliated companies . . .

To continue reading, please subscribe.


We highly value independence. Yuan Talks is solely funded by subscriptions from thousands of intelligent readers like you. Don't miss out! 

What you'll get:

  • Original and in-depth reporting on China's economy and financial markets with details, data and perspectives you don't read elsewhere!
  • Daily Brief newsletter delivered before market open every weekday wrapping up the most important China-related information.
  • Weekly Market Wrap-up on Chinese equities, bonds, the yuan and commodities!
  • Interviews with China experts. We find you insights you should never miss!


Not ready for the full service? Subscribe to our Free Weekly Newsletter first.

Already have an account? Sign In